The controlled-release skincare system VectorHyal™ by Givaudan Active Beauty introduces a new approach to enhancing the performance of cosmetic ingredients through advanced delivery technology. Built on a hyaluronic acid (HA) base, the system uses precision encapsulation to improve ingredient stability while enabling deeper skin penetration.
What sets VectorHyal™ apart is its enzyme-triggered release mechanism, which allows active ingredients to be delivered gradually upon contact with the skin. This ensures longer-lasting efficacy while protecting sensitive compounds from degradation during formulation and storage. The platform is also highly versatile, accommodating both hydrophilic and lipophilic ingredients across formats like serums and creams.
By combining customization, stability, and sensorial appeal, VectorHyal™ reflects a growing shift toward smarter, performance-driven skincare solutions that prioritize both effectiveness and user experience. This innovation signals new opportunities for beauty brands to develop more effective, differentiated formulations that enhance product value and consumer trust.
Image Credit: Givaudan Active Beauty
What Makes This Trend Stand Out
- Enzyme-activated Delivery
- An enzyme-triggered release mechanism that responds to skin-specific enzymes and provides timed delivery and improved stability of sensitive actives.
- Precision Encapsulation
- Nanoscale encapsulation techniques that protect ingredients, modulate penetration depth, and enable compatibility with both hydrophilic and lipophilic actives.
- Sensorial Performance Skincare
- Formulations combining hyaluronic acid matrices with refined textures that enhance perceived luxury while sustaining measurable functional benefits.
Sectors Adopting This
- Consumer Skincare Brands
- Brands seeking differentiation through clinically demonstrable, longer-lasting products driven by intelligent delivery systems and enhanced stability.
- Topical Pharmaceutical Development
- Developers exploring localized controlled-release matrices to improve therapeutic index and minimize systemic exposure for dermal drugs.
- Contract Formulation and Manufacturing
- CDMOs and labs integrating enzyme-responsive platforms to offer expanded services around customization, shelf-life extension, and complex ingredient handling.
